In pan-cancer studies, the high expression and tumor-promoting characteristics of IGF2BP1 in specific tumors make it a promising therapeutic target, but it is also inhibitory in some tumors (Huang et al., 2018). The gene discussed is IGF2BP1; the disease is neoplasm.